

STANDARD TREATMENT WORKFLOW (STW)

ST Elevation Myocardial Infarction (STEMI)

S. K. Dwivedi¹, George Joseph², Aditya Kapoor³, G Karthikeyan⁴, Paul V George⁵, Santhosh Satheesh⁶, Saurabh Mehrotra⁷, Praveen Chandra⁸, Amit M Vora⁹, Calambur Narasimhan¹⁰, Paul V George¹¹, Praveen Chandra¹²

¹King George's Medical University, Lucknow; ²Christian Medical College Vellore; ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow; ⁴All India Institute of Medical Sciences, New Delhi.; ⁵Christian Medical College Vellore; ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Pondyicherry; ⁷Postgraduate Institute of Medical Education and Research, Chandigarh; ⁸Medanta, Gurgaon; ⁹Reliance, Mumbai.; ¹⁰CARE, Hyderabad; ¹¹Christian Medical College Vellore; ¹²Medanta, Gurgaon

CORRESPONDING AUTHOR

Dr SK Dwivedi, King George's Medical University, Lucknow

Email: drskdwivedi60@gmail.com

CITATION

Dwivedi SK, Joseph G, Kapoor A, Karthikeyan G, George PV, Satheesh S, Mehrotra S, Chandra P, Vora AM, Narasimhan C, George PV, Chandra P. ST Elevation Myocardial Infarction (STEMI). Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S211-S212.


DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.106>

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.



October 2018



Standard Treatment Workflow (STW) for the Management of ST ELEVATION MYOCARDIAL INFARCTION (STEMI) ICD-10-I21.3



CONSIDER ANGINA IF

- Diffuse retrosternal pain, heaviness or constriction
- Radiation to arms or neck or back
- Associated with sweating
- Easily reproduced with post-meal exertion
- Consider atypical presentation: Exertional fatigue or breathlessness or profuse sweating or epigastric discomfort/ syncope

More likelihood if known patient of CAD/ multiple risk factors

ACUTE CORONARY SYNDROME:

- Angina at rest or lasting more than 20 minutes
- Recent worsening of stable angina (crescendo) to CCS class III
- New onset effort angina of less than 1 month in CCS class II/ III
- Post infarction angina

ECC: If ST Elevation: Follow ST Elevation MI (STEMI) protocol
If no ST Elevation: UA/NSTEMI


ANGINA UNLIKELY IF:

Variable location or characteristic	Long lasting (hours to days) or short lasting (less than a minute)	Restricted to areas above jaw or below epigastrium	Localized to a point	Pricking or piercing or stabbing type of pain	Precipitated by movement of neck or arms or respiration
-------------------------------------	--	--	----------------------	---	---

PATIENT WITH STEMI WITHIN 12 HOURS

<p>ECG REVEALS ST ELEVATION MI*</p> <p>Refer to primary angioplasty/ thrombolysis capable hospital</p> <p>*Includes new onset LBBB</p>	<p>GENERAL MEASURES</p> <ol style="list-style-type: none"> Admit in ICU equipped with continuous ECG monitoring & defibrillation Routine bio-chemistry and serial cardiac enzymes (troponin) Pain relief by opioid O₂ if saturation less than 90% Aspirin 325 mg, Clopidogrel 300 mg and Atorvastatin 80 mg Echocardiography, particularly for mechanical complication
---	--

<p>PCI CAPABLE HOSPITAL</p> <ol style="list-style-type: none"> Proceed for PCI Radial route preferred Preferably within 90 minutes <p>DURING PROCEDURE</p> <ol style="list-style-type: none"> Use unfractionated heparin No routine thrombosuction Tackle culprit artery only unless shock DES to be preferred <p>POST PROCEDURE</p> <ol style="list-style-type: none"> Continue dual antiplatelets for at least 1 year 	<p>PCI INCAPABLE CENTRE</p> <p>A. Transfer to PCI capable hospital if PCI can be performed within 120 min</p> <p>B. If Transfer to PCI capable hospital not feasible</p> <p>THROMBOLYSE</p> <ol style="list-style-type: none"> Within 12 hours of symptom onset, if no contra-indication Preferably with fibrin specific agent Tenecteplase/ TPA/ Reteplase or Streptokinase, if fibrin-specific are unavailable Therapy to be started within 10 min preferably <p>POST THROMBOLYSIS</p> <ol style="list-style-type: none"> ECG to be done at 60-90 min after starting thrombolysis to assess whether thrombolysis is successful (>50% ST settlement with pain relief) or not If successful, transfer patient for PCI within 3-24 hours If thrombolysis failed, transfer patient immediately for PCI capable hospital Enoxaparin (preferred over unfractionated heparin) to be continued till PCI OR discharge
--	---



PATIENT WITH STEMI IN 12-24 HOURS

Transfer to PCI capable hospital immediately | If ongoing pain, thrombolysis and transfer immediately

PATIENT WITH STEMI AFTER 24 HOURS


Angiography with a view to PCI only if any of following/ Contra indications of angiography:

- Recurrent anginal pain not controlled by medical therapy
- Cardiogenic shock
- Acute LVF
- Mechanical complication
- Dynamic ST-T changes
- Life threatening ventricular arrhythmias

ABSOLUTE CONTRA-INDICATIONS TO THROMBOLYTIC THERAPY:

Previous intra-cerebral hemorrhage or stroke of unknown etiology	Ischemic stroke in last 6 months	CNS neoplasm or AV malformation	Recent (within 1 month) major trauma/surgery/ head injury	Recent (within 1 month) major GI bleed	Known bleeding tendency (except menstrual bleed)	Aortic dissection	Severe uncontrolled hypertension
--	----------------------------------	---------------------------------	---	--	--	-------------------	----------------------------------

<p>DRUGS & DOSAGE</p> <p>Anti-platelets</p> <ol style="list-style-type: none"> Aspirin: Loading dose 325 mg followed by 75 mg OD Clopidogrel: Loading dose 300 mg followed 75 mg OD Prasugrel: Loading dose 60 mg followed by 10 mg OD Ticagrelor: Loading dose 180 mg followed by 90 mg BD <p>Anti-ischemic:</p> <p>Metoprolol: Short acting: 25-100 mg BD Long acting: 25-100 mg OD</p> <p>Nitrates: Isosorbide mono-nitrate 20 to 60 mg in 2 divided dose Nitroglycerine sustained release 2.6 to 6.5 mg BD Nitroglycerine IV 5-25 mcg/ min infusion</p> <p>Statins: High dose Atorvastatin 80 mg OD</p> <p>Ace-inhibitor Ramipril 2.5-10 mg OD Enalapril 2.5-10mg BD</p> <p>Oxygen: If oxygen saturation below 90%</p> <p>Morphine: Titrated in a dose of 2-4 mg IV every 15 minutes</p> <p>Beta-blocker: Oral beta-blocker if LVEF is less than 40%</p>	<p>STEMI DIAGNOSIS*</p> <p>Anti thrombotics:</p> <ol style="list-style-type: none"> Unfractionated heparin: Bolus of 60 U/Kg (maximum 5000 U) followed by 12 U/Kg hourly infusion to maintain APTT at 50-70 sec. Enoxaparin: 1 mg/Kg SC 12 hrly <p>Thrombolytic Therapy:</p> <p>Tenecteplase 35 mg IV bolus if 60-70 Kg 40 mg IV bolus if 70-80 Kg 45 mg IV bolus if more than 80 Kg</p> <p>Reteplase 10 mg IV bolus, repeat after 30 min</p> <p>Alteplase 15 mg IV bolus followed by 0.75 mg/Kg over 30 min upto 50 Kg weight, then 0.5 mg/Kg over 60 min up to 35 mg</p> <p>Streptokinase 1.5 million units IV over 60 min</p>
--	---



*The time point the diagnosis is confirmed with patient history & ECG ideally within 10mins from the First Medical Contact (FMC). All delays are related to FMC.

KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information.
© Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.